Analysis and data insight

Precision Medicine World Conference

Novel Dx companies start to see a better path with payers, but continue to work all the angles

January 23, 2020

SANTA CLARA, Calif. – It has never been easy to get payers to reimburse in a timely and adequate fashion for novel diagnostics, making it notoriously difficult to build a business from them. But a few high-flying diagnostics companies, such as Madison, Wis.-based Exact Sciences Corp. and Redwood City, Calif.-based Guardant Health Inc., have been blazing the trail recently on how to rapidly scale up to become valuable commercial entities from origins as a research-based startup.

Significant year of growth for regenerative medicine sector

January 22, 2020

By Peter Winter

No Comments

According to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), in her delivery of the international advocacy group’s state of the industry briefing at Biotech Showcase in San Francisco, 2019 proved to be a significant year of growth for the regenerative medicine sector.

Quiet conference week, but biopharmas confident about the year ahead

January 21, 2020

By Peter Winter

No Comments

Investors have grown accustomed to hearing news of major announcements from big pharma and blue chip biotech companies during the J.P. Morgan Healthcare conference week. However, as it turned out, headline catalysts were in short supply. In the absence of any major M&A deals taking place, the event turned out to be unusually muted.

Week in review for Jan. 13-17, 2019: A quiet week at the J.P. Morgan Healthcare conference

January 21, 2020

By Peter Winter

No Comments

A quick look back at top stories.

Biggest gainers and losers for the week of Jan. 13-17, 2020

January 17, 2020

No Comments

The top 10 biopharma stock gainers and losers for the week.

M&As and deals up overall in 2019 for med tech, an investor haven in 2020

January 17, 2020

By Karen Carey

No Comments

Last year’s robust deal-making environment, high-value M&As, increasing financings and a supportive public market has set the stage for continued med-tech enthusiasm among investors and partners in 2020.

Regulatory submissions, approvals and other actions: December 2019

January 17, 2020

No Comments

Regulatory decisions affecting biopharma products in development, including approvals, recommendations, rejections and the granting of regulatory pathways in December 2019.

Biopharma money raised: Jan. 1-16, 2020

January 17, 2020

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Money raised by biopharma: 2020 vs. 2019

January 17, 2020

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Boom!

China's financing activity slows as partnering grows, Chinabio say

January 14, 2020

By Michael Fitzhugh

No Comments

SAN FRANCISCO – Pacing the stage at this year's China Showcase Saturday, Chinabio CEO Greg Scott sounded a touch disappointed. Last year lacked the kind of record-breaking stats he likes to punctuate with iconic explosions, a common image in his widely valued China health care talks. "Simply stated, business is continuing as normal," he said.

Analysis and data insight
RSS

Novel Dx companies start to see a better path with payers, but continue to work all the angles

Significant year of growth for regenerative medicine sector

Quiet conference week, but biopharmas confident about the year ahead

Week in review for Jan. 13-17, 2019: A quiet week at the J.P. Morgan Healthcare conference

Biggest gainers and losers for the week of Jan. 13-17, 2020

M&As and deals up overall in 2019 for med tech, an investor haven in 2020

Regulatory submissions, approvals and other actions: December 2019

Biopharma money raised: Jan. 1-16, 2020

Money raised by biopharma: 2020 vs. 2019

China's financing activity slows as partnering grows, Chinabio say

Popular Stories

Insulet to launch wearable insulin pump this year, works with Dexcom iCGM for closed loop

China launches price war to reshuffle pharma industry; Bayer cuts prices by 90% to secure market

Thiel calls for improving research grant, regulatory processes to enhance scientific innovation

Year in Review: From capital markets to CRISPR, 2019 a pretty good year for biopharma

Novavax developing nanoparticle vaccine for Wuhan coronavirus

BioWorld Premium

Analysis and data insight RSS

Popular Stories

BioWorld Premium

Analysis and data insight
RSS